HIV treatment in primary infection: 48 week course modestly delays CD4 drop
The roll-out of male circumcision: reduction in HIV prevalence, condom use maintained
Cognitive impairment still common but ART reduces risk
From 'what if' to 'what now': implementing the new prevention technologies
Maraviroc improves liver fibrosis in HIV/hepatitis C co-infected patients
We have the tools – now we need the money
Treatment as prevention: what are the next steps?
Small study shows women on stable HIV therapy have very low levels of HIV and high drug concentrations in genital fluids
Raltegravir combined with Kaletra associated with good preservation of bone density over 96 weeks
